Q2 2025 · 13F-HR
NEA Management Company, LLCholdings as filed
Filed 2025-08-14 · accession 0000897069-25-001334
$1.33B
Reported value
32
Positions
2025-06-30
Period end
The Brief · NEA Management Company, LLC · Q2 2025
AI · grounded in 13F
NEA Management Company, LLC established a new position in ARCELLX INC ACLXGBX valued at $246.6M. The fund also initiated new stakes in VERONA PHARMA PLC VRNA for $214M and RHYTHM PHARMACEUTICALS INC RYTM for $183.9M. Other new additions include COURSERA INC COUR and CRISPR THERAPEUTICS AG CRSP. Total assets under management stand at $1.3B across 32 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | ARCELLX INC | $246.6M | 18.6% | 3,745,262 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $214.0M | 16.1% | 2,263,138 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $183.9M | 13.8% | 2,909,956 | Common | SOLE |
| 22266M104 | COUR | COURSERA INC | $112.7M | 8.49% | 12,867,769 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $77.2M | 5.81% | 1,587,854 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $72.3M | 5.44% | 13,222,228 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $55.8M | 4.20% | 24,471,264 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $41.8M | 3.15% | 4,118,621 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $41.2M | 3.10% | 3,614,486 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $34.7M | 2.61% | 7,692,298 | Common | SOLE |
| 05156V102 | AUPH | AURINIA PHARMACEUTICALS INC | $33.6M | 2.53% | 3,969,834 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $30.6M | 2.31% | 2,294,261 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $26.5M | 1.99% | 2,733,719 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $22.3M | 1.68% | 18,093,034 | Common | SOLE |
| 10920V404 | — | NEUEHEALTH INC | $18.8M | 1.42% | 2,726,917 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $18.8M | 1.42% | 1,960,169 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $13.6M | 1.03% | 1,090,793 | Common | SOLE |
| 15870P307 | CSBR | CHAMPIONS ONCOLOGY INC | $12.6M | 0.95% | 1,713,720 | Common | SOLE |
| 126638105 | CVRX | CVRX INC | $11.9M | 0.90% | 2,026,083 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $11.0M | 0.83% | 4,448,757 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $9.8M | 0.73% | 2,437,689 | Common | SOLE |
| 81726A209 | — | SENTI BIOSCIENCES INC | $8.0M | 0.60% | 3,775,615 | Common | SOLE |
| 68170A108 | OMDA | OMADA HEALTH INC | $6.7M | 0.50% | 364,115 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $5.9M | 0.45% | 3,568,781 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $4.7M | 0.35% | 1,462,586 | Common | SOLE |
| 00653A107 | ADAPY | ADAPTIMMUNE THERAPEUTICS PLC | $4.1M | 0.31% | 17,079,778 | Common | SOLE |
| 87166L209 | SYBX | SYNLOGIC INC | $3.7M | 0.28% | 2,922,772 | Common | SOLE |
| 57055L206 | MRKR | MARKER THERAPEUTICS INC | $2.5M | 0.19% | 1,625,678 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $1.1M | 0.09% | 478,548 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $949,162 | 0.07% | 499,559 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $804,084 | 0.06% | 600,063 | Common | SOLE |
| 96328L205 | 2CH | WHEELS UP EXPERIENCE INC | $113,554 | 0.01% | 106,125 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.